These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 30881511)
1. Immunohistochemical expression and clinicopathological assessment of the cancer testis antigens NY-ESO-1 and MAGE-A4 in high-grade soft-tissue sarcoma. Kakimoto T; Matsumine A; Kageyama S; Asanuma K; Matsubara T; Nakamura T; Iino T; Ikeda H; Shiku H; Sudo A Oncol Lett; 2019 Apr; 17(4):3937-3943. PubMed ID: 30881511 [TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical expression and clinicopathological assessment of PD-1, PD-L1, NY-ESO-1, and MAGE-A4 expression in highly aggressive soft tissue sarcomas. Hashimoto K; Nishimura S; Ito T; Kakinoki R; Akagi M Eur J Histochem; 2022 Apr; 66(2):. PubMed ID: 35448937 [TBL] [Abstract][Full Text] [Related]
3. Clinicopathological Assessment of Cancer/Testis Antigens NY-ESO-1 and MAGE-A4 in Highly Aggressive Soft Tissue Sarcomas. Hashimoto K; Nishimura S; Ito T; Akagi M Diagnostics (Basel); 2022 Mar; 12(3):. PubMed ID: 35328286 [TBL] [Abstract][Full Text] [Related]
4. Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1. Iura K; Maekawa A; Kohashi K; Ishii T; Bekki H; Otsuka H; Yamada Y; Yamamoto H; Harimaya K; Iwamoto Y; Oda Y Hum Pathol; 2017 Mar; 61():130-139. PubMed ID: 27993576 [TBL] [Abstract][Full Text] [Related]
5. Myeloid-derived suppressor cells infiltration in non-small-cell lung cancer tumor and MAGE-A4 and NY-ESO-1 expression. Hou Z; Liang X; Wang X; Zhou Z; Shi G Oncol Lett; 2020 Jun; 19(6):3982-3992. PubMed ID: 32382343 [TBL] [Abstract][Full Text] [Related]
6. Clinicopathological assessment of cancer/testis antigens NY‑ESO‑1 and MAGE‑A4 in osteosarcoma. Hashimoto K; Nishimura S; Ito T; Oka N; Kakinoki R; Akagi M Eur J Histochem; 2022 Jun; 66(3):. PubMed ID: 35736245 [TBL] [Abstract][Full Text] [Related]
7. MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours. Ishihara M; Kageyama S; Miyahara Y; Ishikawa T; Ueda S; Soga N; Naota H; Mukai K; Harada N; Ikeda H; Shiku H BMC Cancer; 2020 Jun; 20(1):606. PubMed ID: 32600281 [TBL] [Abstract][Full Text] [Related]
8. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study. Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695 [TBL] [Abstract][Full Text] [Related]
9. Brief Communication on MAGE-A4 and Coexpression of Cancer Testis Antigens in Metastatic Synovial Sarcomas: Considerations for Development of Immunotherapeutics. Vanacker H; Connacher R; Meurgey A; Bollard J; Attignon V; Tirode F; Jean-Denis M; Brahmi M; Blay JY; Wang R; Williams D; Dufresne A J Immunother; 2025 Jan; 48(1):27-31. PubMed ID: 39224047 [TBL] [Abstract][Full Text] [Related]
10. Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7. Jungbluth AA; Antonescu CR; Busam KJ; Iversen K; Kolb D; Coplan K; Chen YT; Stockert E; Ladanyi M; Old LJ Int J Cancer; 2001 Oct; 94(2):252-6. PubMed ID: 11668506 [TBL] [Abstract][Full Text] [Related]
11. Involvement of NY-ESO-1 and MAGE-A4 in the pathogenesis of desmoid tumors. Hashimoto K; Nishimura S; Shinyashiki Y; Ito T; Kakinoki R; Akagi M Medicine (Baltimore); 2023 Jun; 102(22):e33908. PubMed ID: 37266606 [TBL] [Abstract][Full Text] [Related]
12. Limited expression of cancer-testis antigens in renal cell carcinoma patients. Soga N; Hori Y; Yamakado K; Ikeda H; Imai N; Kageyama S; Nakase K; Yuta A; Hayashi N; Shiku H; Sugimura Y Mol Clin Oncol; 2013 Mar; 1(2):326-330. PubMed ID: 24649170 [TBL] [Abstract][Full Text] [Related]
13. Case-Control Study: Smoking History Affects the Production of Tumor Antigen-Specific Antibodies NY-ESO-1 in Patients with Lung Cancer in Comparison with Cancer Disease-Free Group. Myšíková D; Adkins I; Hradilová N; Palata O; Šimonek J; Pozniak J; Kolařík J; Skallová-Fialová A; Špíšek R; Lischke R J Thorac Oncol; 2017 Feb; 12(2):249-257. PubMed ID: 27793776 [TBL] [Abstract][Full Text] [Related]
14. MAGEA4 expression in bone and soft tissue tumors: its utility as a target for immunotherapy and diagnostic marker combined with NY-ESO-1. Iura K; Kohashi K; Ishii T; Maekawa A; Bekki H; Otsuka H; Yamada Y; Yamamoto H; Matsumoto Y; Iwamoto Y; Oda Y Virchows Arch; 2017 Sep; 471(3):383-392. PubMed ID: 28744588 [TBL] [Abstract][Full Text] [Related]
15. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms. Yakirevich E; Sabo E; Lavie O; Mazareb S; Spagnoli GC; Resnick MB Clin Cancer Res; 2003 Dec; 9(17):6453-60. PubMed ID: 14695148 [TBL] [Abstract][Full Text] [Related]
16. Expression of MAGE-A and NY-ESO-1 in Primary and Metastatic Cancers. Park TS; Groh EM; Patel K; Kerkar SP; Lee CC; Rosenberg SA J Immunother; 2016 Jan; 39(1):1-7. PubMed ID: 26641256 [TBL] [Abstract][Full Text] [Related]
17. NY-ESO-1 antigen expression and immune response are associated with poor prognosis in MAGE-A4-vaccinated patients with esophageal or head/neck squamous cell carcinoma. Ueda S; Miyahara Y; Nagata Y; Sato E; Shiraishi T; Harada N; Ikeda H; Shiku H; Kageyama S Oncotarget; 2018 Nov; 9(89):35997-36011. PubMed ID: 30542513 [TBL] [Abstract][Full Text] [Related]
18. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance. Yoshida N; Abe H; Ohkuri T; Wakita D; Sato M; Noguchi D; Miyamoto M; Morikawa T; Kondo S; Ikeda H; Nishimura T Int J Oncol; 2006 May; 28(5):1089-98. PubMed ID: 16596224 [TBL] [Abstract][Full Text] [Related]
19. Immunohystochemical expression of cancer/testis antigens (MAGE-A3/4, NY-ESO-1) in non-small cell lung cancer: the relationship with clinical-pathological features. Grah J; Samija M; Juretić A; Sarcević B; Sobat H Coll Antropol; 2008 Sep; 32(3):731-6. PubMed ID: 18982744 [TBL] [Abstract][Full Text] [Related]
20. Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma. Iura K; Kohashi K; Hotokebuchi Y; Ishii T; Maekawa A; Yamada Y; Yamamoto H; Iwamoto Y; Oda Y J Pathol Clin Res; 2015 Jul; 1(3):144-59. PubMed ID: 27499900 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]